Government-Owned Inventions; Availability for Licensing, 70195-70196 [2014-27820]

Download as PDF 70195 Federal Register / Vol. 79, No. 227 / Tuesday, November 25, 2014 / Notices ESTIMATED ANNUALIZED BURDEN HOURS Estimated annual number of respondents Number of responses per respondent Average burden per response (in hours) Total annual burden hours Type of respondent Form name Laboratory Personnel Using Bulk Submission ..... Minimal Fields .............. Optional Fields ............. Minimal Fields .............. 190 159 116 29 29 29 18/60 14/60 30/60 1,653 1,076 1,682 Optional Fields ............. 97 29 24/60 1,125 Laboratory Personnel Not Using Bulk Submission. Dated: November 17, 2014. Lawrence A. Tabak, Principal Deputy Director, National Institutes of Health. [FR Doc. 2014–27898 Filed 11–24–14; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, HHS. ACTION: Notice. The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. FOR FURTHER INFORMATION CONTACT: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: 301– 496–7057; fax: 301–402–0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications. SUPPLEMENTARY INFORMATION: Technology descriptions follow. wreier-aviles on DSK4TPTVN1PROD with NOTICES SUMMARY: T-cell Chimeric Receptors of TSLPR for Diagnosis and Immunotherapy of Cancer Description of Technology: T-cellbased immunotherapies allow a patient’s immune system to concentrate its efforts and destroy cancer cells. In the present technology, the researchers VerDate Sep<11>2014 14:41 Nov 24, 2014 Jkt 235001 at the National Cancer Institute have developed chimeric antigen receptors (or CARs), which encode an antigen binding domain specific for thymic stromal lymphopoietin receptor (TSLPR) and a T-cell signaling domain. TSLPR is over-expressed on the surface of approximately 10% of adult and pediatric B-cell precursor acute lymphoblastic leukemias (BCP–ALL). Available for licensing is the abovereference CAR technology as well as methods for diagnosing and treating cancer using these CARs. Potential Commercial Applications: • Immunotherapy against cancer, especially leukemia • Immunotoxins Competitive Advantages: CAR receptors are specific for TSLPR. Development Stage: • In vitro data available • In vivo data available (animal) • Prototype Inventors: Terry Fry and Haiying Qin (NCI). Publication: Qin H, et al. Pre-clinical development of a novel chimerical antigen receptor targeting high-risk pediatric ALL over-expressing Tslpr. Blood 2013 Nov 15;122(21):2665. Intellectual Property: • HHS Reference No. E–008–2014/0— US Provisional Application No. 61/ 912,948 filed 06 Dec 2013 • HHS Reference No. E–008–2014/1— US Provisional Application No. 61/ 991,697 filed 12 May 2014 • HHS Reference No. E–008–2014/2— PCT Application No. PCT/US2014/ 063096 filed 30 Oct 2014 Licensing Contact: Patrick McCue, Ph.D.; 301–435–5560; mccuepat@ mail.nih.gov Novel Bridged Bicyclic Thiazepinone Compounds Description of Technology: The invention is directed to small molecules containing a novel, bridged, bicyclic thiazepinone pharmacophore. Invention compounds inhibit the Nav1.7 sodium channel. Additionally, invention compounds bind the human norepinephrine transporter (NET), with PO 00000 Frm 00040 Fmt 4703 Sfmt 4703 selectivity over the serotonin transporter (SERT) and dopamine transporter (DAT). Invention compounds could be used to treat neuropathic pain associated with diabetes and fibromyalgia, Attention Deficit Hyperactivity Disorder (ADHD), urinary incontinence, depression, anxiety, and other mood disorders. Invention compounds can be conjugated with fluorescent or radioactive tags, and used to probe the structure and activity of the Nav1.7 sodium channel and NET. Potential Commercial Applications: • Therapeutic • Chemical probe Competitive Advantages: • Small molecule compounds made using facile synthesis scheme • Inhibition of Nav1.7 sodium channel • NET inhibition with selectivity over other transporters Development Stage: • Early-stage • In vitro data available Inventors: Hans F. Luecke (NIDDK), Michael T. Scerba (NIDDK), Dongwook Kang (Daegu Catholic University). Intellectual Property: HHS Reference No. E–224–2012/0— • US Application No. 61/876,262 filed 09 Sept 2013 • PCT Application No. PCT/US2014/ 054660 filed 09 Sept 2014 Licensing Contact: Lauren NguyenAntczak, Ph.D., J.D.; 301–435–4074; nguyenantczakla@mail.nih.gov. Collaborative Research Opportunity: The National Institute of Diabetes and Digestive and Kidney Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize use of bridged bicyclic thiazepinones. For collaboration opportunities, please contact Marguerite J. Miller, M.B.A. at marguerite.miller@nih.gov or 301–496– 9003. E:\FR\FM\25NON1.SGM 25NON1 70196 Federal Register / Vol. 79, No. 227 / Tuesday, November 25, 2014 / Notices Dated: November 18, 2014. Richard U. Rodriguez, Acting Director, Office of Technology Transfer, National Institutes of Health. [FR Doc. 2014–27820 Filed 11–24–14; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center for Scientific Review; Notice of Closed Meetings wreier-aviles on DSK4TPTVN1PROD with NOTICES Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Center for Scientific Review Special Emphasis Panel; Topics in Clinical Research and Field Studies of Infectious Diseases. Date: December 2, 2014. Time: 4:00 p.m. to 4:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call). Contact Person: Soheyla Saadi, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3211, MSC 7808, Bethesda, MD 20892, 301–435– 0903, saadisoh@csr.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. Name of Committee: Center for Scientific Review Special Emphasis Panel; Development and Testing of Novel Interventions to Improve HIV Prevention, Care and Program Implementation. Date: December 3, 2014. Time: 2:00 p.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call). Contact Person: Mark P. Rubert, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5218, MSC 7852, Bethesda, MD 20892, 301–435– 1775, rubertm@csr.nih.gov. VerDate Sep<11>2014 14:41 Nov 24, 2014 Jkt 235001 This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. Name of Committee: Center for Scientific Review Special Emphasis Panel; RFA Panel: Tobacco Control Regulatory Research. Date: December 4, 2014. Time: 9:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications and/or proposals. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892. Contact Person: Mark P. Rubert, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5218, MSC 7852, Bethesda, MD 20892, 301–435– 1775, rubertm@csr.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. Name of Committee: Center for Scientific Review Special Emphasis Panel; RFA Panel: Tobacco Control Regulatory Research. Date: December 5, 2014. Time: 8:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: Washington Marriott at Metro Center, 775 12th St. NW., Washington, DC 20005. Contact Person: Shiv A. Prasad, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5220, MSC 7852, Bethesda, MD 20892, 301–443– 5779, prasads@csr.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: AIDS and AIDS Related Research. Date: December 8–9, 2014. Time: 10:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Virtual Meeting). Contact Person: Robert Freund, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5216, MSC 7852, Bethesda, MD 20892, 301–435– 1050, freundr@csr.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. Name of Committee: Center for Scientific Review Special Emphasis Panel; Small Business: HIV/AIDS Innovative Research Applications. Date: December 8, 2014. Time: 11:00 a.m. to 2:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Virtual Meeting). PO 00000 Frm 00041 Fmt 4703 Sfmt 4703 Contact Person: Mark P. Rubert, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5218, MSC 7852, Bethesda, MD 20892, 301–435– 1775, rubertm@csr.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. Name of Committee: Center for Scientific Review Special Emphasis Panel; Program Project: AIDS and AIDS Related Research. Date: December 9, 2014. Time: 1:00 p.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Virtual Meeting). Contact Person: Kenneth A. Roebuck, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5106, MSC 7852, Bethesda, MD 20892, (301) 435– 1166, roebuckk@csr.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) Dated: November 19, 2014. David Clary, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2014–27818 Filed 11–24–14; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Aging; Amended Notice of Meeting Notice is hereby given of a change in the meeting of the National Institute on Aging Special Emphasis Panel, November 17, 2014, 11:00 a.m. to November 17, 2014, 03:00 p.m., National Institute on Aging, Gateway Building, 7201 Wisconsin Avenue, Suite 2C212, Bethesda, MD 20892 which was published in the Federal Register on September 17, 2014 (79 FR 55817). The meeting notice is amended to change the date of the meeting from November 17, 2014 to December 8, 2014 at 12:00 p.m. to 4:00 p.m. The meeting is closed to the public. E:\FR\FM\25NON1.SGM 25NON1

Agencies

[Federal Register Volume 79, Number 227 (Tuesday, November 25, 2014)]
[Notices]
[Pages 70195-70196]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-27820]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Licensing information and copies of 
the U.S. patent applications listed below may be obtained by writing to 
the indicated licensing contact at the Office of Technology Transfer, 
National Institutes of Health, 6011 Executive Boulevard, Suite 325, 
Rockville, Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402-
0220. A signed Confidential Disclosure Agreement will be required to 
receive copies of the patent applications.

SUPPLEMENTARY INFORMATION: Technology descriptions follow.

T-cell Chimeric Receptors of TSLPR for Diagnosis and Immunotherapy of 
Cancer

    Description of Technology: T-cell-based immunotherapies allow a 
patient's immune system to concentrate its efforts and destroy cancer 
cells. In the present technology, the researchers at the National 
Cancer Institute have developed chimeric antigen receptors (or CARs), 
which encode an antigen binding domain specific for thymic stromal 
lymphopoietin receptor (TSLPR) and a T-cell signaling domain. TSLPR is 
over-expressed on the surface of approximately 10% of adult and 
pediatric B-cell precursor acute lymphoblastic leukemias (BCP-ALL).
    Available for licensing is the above-reference CAR technology as 
well as methods for diagnosing and treating cancer using these CARs.
    Potential Commercial Applications:

 Immunotherapy against cancer, especially leukemia
 Immunotoxins

    Competitive Advantages: CAR receptors are specific for TSLPR.
    Development Stage:

 In vitro data available
 In vivo data available (animal)
 Prototype

    Inventors: Terry Fry and Haiying Qin (NCI).
    Publication: Qin H, et al. Pre-clinical development of a novel 
chimerical antigen receptor targeting high-risk pediatric ALL over-
expressing Tslpr. Blood 2013 Nov 15;122(21):2665.
    Intellectual Property:

 HHS Reference No. E-008-2014/0--US Provisional Application No. 
61/912,948 filed 06 Dec 2013
 HHS Reference No. E-008-2014/1--US Provisional Application No. 
61/991,697 filed 12 May 2014
 HHS Reference No. E-008-2014/2--PCT Application No. PCT/
US2014/063096 filed 30 Oct 2014

    Licensing Contact: Patrick McCue, Ph.D.; 301-435-5560; 
mccuepat@mail.nih.gov

Novel Bridged Bicyclic Thiazepinone Compounds

    Description of Technology: The invention is directed to small 
molecules containing a novel, bridged, bicyclic thiazepinone 
pharmacophore. Invention compounds inhibit the Nav1.7 sodium channel. 
Additionally, invention compounds bind the human norepinephrine 
transporter (NET), with selectivity over the serotonin transporter 
(SERT) and dopamine transporter (DAT).
    Invention compounds could be used to treat neuropathic pain 
associated with diabetes and fibromyalgia, Attention Deficit 
Hyperactivity Disorder (ADHD), urinary incontinence, depression, 
anxiety, and other mood disorders.
    Invention compounds can be conjugated with fluorescent or 
radioactive tags, and used to probe the structure and activity of the 
Nav1.7 sodium channel and NET.
    Potential Commercial Applications:

 Therapeutic
 Chemical probe

    Competitive Advantages:

 Small molecule compounds made using facile synthesis scheme
 Inhibition of Nav1.7 sodium channel
 NET inhibition with selectivity over other transporters

    Development Stage:

 Early-stage
 In vitro data available
    Inventors: Hans F. Luecke (NIDDK), Michael T. Scerba (NIDDK), 
Dongwook Kang (Daegu Catholic University).

Intellectual Property: HHS Reference No. E-224-2012/0--
 US Application No. 61/876,262 filed 09 Sept 2013
 PCT Application No. PCT/US2014/054660 filed 09 Sept 2014

    Licensing Contact: Lauren Nguyen-Antczak, Ph.D., J.D.; 301-435-
4074; nguyenantczakla@mail.nih.gov.
    Collaborative Research Opportunity: The National Institute of 
Diabetes and Digestive and Kidney Diseases is seeking statements of 
capability or interest from parties interested in collaborative 
research to further develop, evaluate or commercialize use of bridged 
bicyclic thiazepinones. For collaboration opportunities, please contact 
Marguerite J. Miller, M.B.A. at marguerite.miller@nih.gov or 301-496-
9003.


[[Page 70196]]


    Dated: November 18, 2014.
Richard U. Rodriguez,
Acting Director, Office of Technology Transfer, National Institutes of 
Health.
[FR Doc. 2014-27820 Filed 11-24-14; 8:45 am]
BILLING CODE 4140-01-P